Literature DB >> 19397907

(1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.

Raymond G Booth1, Lijuan Fang, Yingsu Huang, Andrzej Wilczynski, Sashikala Sivendran.   

Abstract

The serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) G protein-coupled receptors signal primarily through G alpha(q) to activate phospholipase C (PLC) and formation of inositol phosphates (IP) and diacylglycerol. The human 5-HT(2C) receptor, expressed exclusively in the central nervous system, is involved in several physiological and psychological processes. Development of 5-HT(2C) agonists that do not also activate 5-HT(2A) or 5-HT(2B) receptors is challenging because transmembrane domain identity is about 75% among 5-HT(2) subtypes. This paper reports 5-HT(2) receptor affinity and function of (1R,3S)-(-)-trans-1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene (PAT), a small molecule that produces anorexia and weight-loss after peripheral administration to mice. (-)-Trans-PAT is a stereoselective full-efficacy agonist at human 5-HT(2C) receptors, plus, it is a 5-HT(2A)/5-HT(2B) inverse agonist and competitive antagonist. The K(i) of (-)-trans-PAT at 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptors is 410, 1200, and 37 nM, respectively. Functional studies measured activation of PLC/[(3)H]-IP formation in clonal cells expressing human 5-HT(2) receptors. At 5-HT(2C) receptors, (-)-trans-PAT is an agonist (EC(50) = 20 nM) comparable to serotonin in potency and efficacy. At 5-HT(2A) and 5-HT(2B) receptors, (-)-trans-PAT is an inverse agonist (IC(50) = 490 and 1,000 nM, respectively) and competitive antagonist (K(B) = 460 and 1400 nM, respectively) of serotonin. Experimental results are interpreted in light of molecular modeling studies indicating the (-)-trans-PAT protonated amine can form an ionic bond with D3.32 of 5-HT(2A) and 5-HT(2C) receptors, but, not with 5-HT(2B) receptors. In addition to probing 5-HT(2) receptor structure and function, (-)-trans-PAT is a novel lead regarding 5-HT(2C) agonist/5-HT(2A) inverse agonist drug development for obesity and neuropsychiatric disorders.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19397907      PMCID： PMC2749987          DOI： 10.1016/j.ejphar.2009.04.035

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN： 0014-2999            Impact factor:   4.432


  40 in total

1.  5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease.

Authors:  S H Fox; J M Brotchie
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

Review 2.  Multiplicity of mechanisms of serotonin receptor signal transduction.

Authors:  J R Raymond; Y V Mukhin; A Gelasco; J Turner; G Collinsworth; T W Gettys; J S Grewal; M N Garnovskaya
Journal:  Pharmacol Ther       Date:  2001 Nov-Dec       Impact factor: 12.310

3.  Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography.

Authors:  Tetsuji Okada; Yoshinori Fujiyoshi; Maria Silow; Javier Navarro; Ehud M Landau; Yoshinori Shichida
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-23       Impact factor: 11.205

4.  Evidence that hypophagia induced by d-fenfluramine and d-norfenfluramine in the rat is mediated by 5-HT2C receptors.

Authors:  S P Vickers; C T Dourish; G A Kennett
Journal:  Neuropharmacology       Date:  2001-08       Impact factor: 5.250

Review 5.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.

Authors:  J A Ballesteros; L Shi; J A Javitch
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

6.  Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding.

Authors:  Paul J Fletcher; Andrew J Grottick; Guy A Higgins
Journal:  Neuropsychopharmacology       Date:  2002-10       Impact factor: 7.853

7.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.

Authors:  L W Fitzgerald; T C Burn; B S Brown; J P Patterson; M H Corjay; P A Valentine; J H Sun; J R Link; I Abbaszade; J M Hollis; B L Largent; P R Hartig; G F Hollis; P C Meunier; A J Robichaud; D W Robertson
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

8.  5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat.

Authors:  S H Fox; J M Brotchie
Journal:  Eur J Pharmacol       Date:  2000-06-09       Impact factor: 4.432

9.  Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension.

Authors:  J-M Launay; P Hervé; K Peoc'h; C Tournois; J Callebert; C G Nebigil; N Etienne; L Drouet; M Humbert; G Simonneau; L Maroteaux
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

Review 10.  Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse.

Authors:  Marcy J Bubar; Kathryn A Cunningham
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453
View more
  21 in total

1.  HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.

Authors:  Alan P Kozikowski; Sung Jin Cho; Niels H Jensen; John A Allen; Andreas M Svennebring; Bryan L Roth
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

2.  Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity.

Authors:  Gang Chen; Sung Jin Cho; Xi-Ping Huang; Niels H Jensen; Andreas Svennebring; Maria F Sassano; Bryan L Roth; Alan P Kozikowski
Journal:  ACS Med Chem Lett       Date:  2011-10-10       Impact factor: 4.345

3.  A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.

Authors:  Clinton E Canal; Drake Morgan; Daniel Felsing; Krishnakanth Kondabolu; Neil E Rowland; Kimberly L Robertson; Rajeev Sakhuja; Raymond G Booth
Journal:  J Pharmacol Exp Ther       Date:  2014-02-21       Impact factor: 4.030

4.  Long-term consumption of fish oil-enriched diet impairs serotonin hypophagia in rats.

Authors:  Regina L H Watanabe; Iracema S Andrade; Mônica M Telles; Kelse T Albuquerque; Cláudia M O Nascimento; Lila M Oyama; Dulce E Casarini; Eliane B Ribeiro
Journal:  Cell Mol Neurobiol       Date:  2010-06-05       Impact factor: 5.046

Review 5.  5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.

Authors:  Stephanie W Watts; Robert Patrick Davis
Journal:  Cardiovasc Ther       Date:  2011-02       Impact factor: 3.023

6.  Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens.

Authors:  James M Kasper; Raymond G Booth; Joanna Peris
Journal:  Synapse       Date:  2014-11-20       Impact factor: 2.562

7.  The serotonin-2 receptor modulator, (-)-trans-PAT, decreases voluntary ethanol consumption in rats.

Authors:  James Kasper; Rajiv Tikamdas; Myong Sang Kim; Kaley Macfadyen; Richard Aramini; Joseph Ladd; Sarah Bisceglia; Raymond Booth; Joanna Peris
Journal:  Eur J Pharmacol       Date:  2013-09-13       Impact factor: 4.432

8.  Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice.

Authors:  Neil E Rowland; Erica M Crump; Nancy Nguyen; Kimberly Robertson; Zhuming Sun; Raymond G Booth
Journal:  Pharmacol Biochem Behav       Date:  2008-07-19       Impact factor: 3.533

9.  Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.

Authors:  Kathryn A Cunningham; Noelle C Anastasio; Robert G Fox; Sonja J Stutz; Marcy J Bubar; Sarah E Swinford; Cheryl S Watson; Scott R Gilbertson; Kenner C Rice; Sharon Rosenzweig-Lipson; F Gerard Moeller
Journal:  ACS Chem Neurosci       Date:  2012-08-11       Impact factor: 4.418

10.  Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.

Authors:  Clinton E Canal; Raymond G Booth; Drake Morgan
Journal:  Neuropharmacology       Date:  2013-01-23       Impact factor: 5.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.